EMERYVILLE, Calif., May 31, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage biotechnology company developing first-in-class “non-antibiotic anti-infective” products for the treatment and prevention of topical infections, today announced three new composition of matter patent issuances in Australia, New Zealand and Mexico and four Notices of Allowance in Canada, Japan, South Africa and Mexico on its proprietary Aganocide compounds which includes its lead compound, NVC-422.
